These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3957968)

  • 41. Heparin-modified dendrimer cross-linked collagen matrices for the delivery of basic fibroblast growth factor (FGF-2).
    Princz MA; Sheardown H
    J Biomater Sci Polym Ed; 2008; 19(9):1201-18. PubMed ID: 18727861
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of an antithrombogenic cardiac wall substitute which can be reconstructed by infiltration of host cells.
    Okoshi T; Noishiki Y; Tomizawa Y; Morishima M; Koyanagi H
    ASAIO Trans; 1988; 34(3):532-7. PubMed ID: 3196559
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Application of an antithrombogenic Anthron bypass tube to experimental orthotopic liver transplantation. Studies on blood coagulation and fibrinolysis.
    Nakao A; Kano T; Nonami T; Harada A; Ohkura K; Takagi H; Kondo T; Mori Y
    ASAIO Trans; 1986; 32(1):503-7. PubMed ID: 3535852
    [No Abstract]   [Full Text] [Related]  

  • 44. An in vitro-formed protamine-heparin complex as a model for a two-compartment store for biogenic amines.
    Uvnäs B; Aborg CH
    Acta Physiol Scand; 1976 Apr; 96(4):512-25. PubMed ID: 5849
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Surface-immobilized heparin prevents platelet coagulation].
    Nystrand A
    Lakartidningen; 1991 Jan; 88(4):237-40. PubMed ID: 1994172
    [No Abstract]   [Full Text] [Related]  

  • 46. Evaluation of an epoxy-fixed biological patch with ionically bound heparin as a pericardial substitute.
    Sung HW; Chang Y; Chiu YT; Hsu HL; Shih CC; Lu JH; Yang PC
    Biomaterials; 1996 Sep; 17(17):1693-701. PubMed ID: 8866031
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Antibacterial vascular prosthesis with anticoagulant properties and their application in infected wounds (experimental study)].
    Nikolaev AV; Sychenikov IA; Shekhter AB; Mamedov LA; Iakunin GA
    Grudn Khir; 1977; (6):36-41. PubMed ID: 608596
    [No Abstract]   [Full Text] [Related]  

  • 48. Development of Anthron, an antithrombogenic coating for angiographic catheters.
    Nagaoka S; Noishiki Y
    J Biomater Appl; 1989 Jul; 4(1):3-21. PubMed ID: 2746467
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [A simple method for the quantitative determination of heparin by titration with protamine].
    KALLER H
    Arch Int Pharmacodyn Ther; 1954 Sep; 99(2):163-74. PubMed ID: 13229427
    [No Abstract]   [Full Text] [Related]  

  • 50. [Composition and properties of heparin and protamine complexes formed in the plasma].
    Roszkowska-Jakimiec W
    Acta Haematol Pol; 1985; 16(1-2):65-71. PubMed ID: 3832743
    [No Abstract]   [Full Text] [Related]  

  • 51. Long-term stability in vivo of a thromboresistant heparinized surface.
    Arnander C; Bagger-Sjöbäck D; Frebelius S; Larsson R; Swedenborg J
    Biomaterials; 1987 Nov; 8(6):496-9. PubMed ID: 3427150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mode of binding of histamine and some other biogenic amines to a protamine-heparin complex in vitro.
    Aborg CH; Uvnäs B
    Acta Physiol Scand; 1968 Dec; 74(4):552-67. PubMed ID: 5735618
    [No Abstract]   [Full Text] [Related]  

  • 53. [Importance of agents modifying blood lipids; effect of heparin and protamine sulfate].
    DE GENNES JL
    Presse Med (1893); 1957 Jan; 65(8):153-5. PubMed ID: 13420036
    [No Abstract]   [Full Text] [Related]  

  • 54. [Heparin and protamine in extracorporeal circulation].
    SATTER P
    Thoraxchirurgie; 1961 Feb; 8():499-503. PubMed ID: 13746734
    [No Abstract]   [Full Text] [Related]  

  • 55. Correlation of the serial-dilution protamine sulfate test with models of "hypercoagulability" and thrombosis in dogs.
    Francis PB; Wilson JE
    Am J Clin Pathol; 1977 Apr; 67(4):356-61. PubMed ID: 322471
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative study of cardiac and vascular implants in relation to thrombosis.
    Hufnagel CA; Conrad PW; Gillespie JF; Pifarre R; Ilano A; Yokoyama T
    Surgery; 1967 Jan; 61(1):11-6. PubMed ID: 6016658
    [No Abstract]   [Full Text] [Related]  

  • 57. Development of a small caliber vascular graft by a new crosslinking method incorporating slow heparin release collagen and natural tissue compliance.
    Noishiki Y; Miyata T; Kodaira K
    ASAIO Trans; 1986; 32(1):114-9. PubMed ID: 3778694
    [No Abstract]   [Full Text] [Related]  

  • 58. [Duration of action, protamine neutralization and urinary elimination of intramuscular heparin in aqueous solution].
    DE NICOLA P
    Farmaco Sci Tec; 1951; 6(1):51-7. PubMed ID: 14823026
    [No Abstract]   [Full Text] [Related]  

  • 59. Protamine-heparin complex as a substrate for plasmin.
    GREIG HB; CORNELIUS EM
    Biochim Biophys Acta; 1963 Apr; 67():658-68. PubMed ID: 13950275
    [No Abstract]   [Full Text] [Related]  

  • 60. The assay of protamine sulphate for its capacity to neutralise heparin.
    BIRKINSHAW VJ; SMITH KL
    J Pharm Pharmacol; 1962 Dec; 14(Suppl)():95T-96T. PubMed ID: 13971139
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.